Canada markets closed

SomaLogic, Inc. (SLGCW)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
0.7600-0.0500 (-6.17%)
At close: 09:38AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.8100
Bid0.0000 x 3200
Ask0.0000 x 1000
Day's Range0.7600 - 0.7600
52 Week Range0.7600 - 0.7600
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    SomaLogic Announces License Agreement with OncoHost for the Development of Precision Cancer Diagnostics

    BOULDER, Colo. and BINYAMINA, Israel, June 13, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced it has signed a licensing agreement with OncoHost, a global leader in next-generation precision oncology for personalized cancer therapy. As part of the agreement, OncoHost will license SomaLogic’s SomaScan® Platform to develop proteomics tests for its PROphet® diagnostic system, designed to predict patient response to immunotherapy trea

  • GlobeNewswire

    SomaLogic Announces June Conference Participation

    BOULDER, Colo., June 01, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the following conferences. Jefferies Healthcare ConferenceJune 8-9, 2022, in New York 7th Annual MarketsandMarkets Biomarker and Companion Diagnostics ConferenceJoe Gogain, Director, Clinical R&D will present “Bigger data = better data. Detect 7,000 proteins at once with high throughput to optimize biomarker discover” durin

  • GlobeNewswire

    SomaLogic Reports First Quarter 2022 Financial Results

    Company to host conference call today at 4:30 p.m. ETBOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter ended March 31, 2022. “Our successful first quarter has kickstarted another exciting year for SomaLogic as we continue to apply the power of the human proteome to improve health and disease management,” said Roy Smythe, M.D., SomaLogic’s Chief Executive Officer. “We have already re